Aspen Expects Growth Following Sandoz And Viatris Deals

Reshaped Business Expects To See Significant Growth In First Half

 
• By Dave Wallace

Aspen expects to report significant growth in its continuing operations for the first half of its financial year, following deals with Sandoz and Viatris that have seen the South African firm divest major businesses in Japan and Europe.

Lego Bricks Stairs Steps Hand
Through divestments, Aspen has restructured its business for growth • Source: Shutterstock

South Africa’s Aspen Pharmacare says it expects to report growth for its continuing operations of between 16% and 18% for the six months ended 31 December 2020, following major divestments that have seen the company offload businesses in Japan and Europe to Sandoz and Viatris’ Mylan.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business